Share Twitter LinkedIn Facebook Email Eric Van Cutsem, MD of University of Leuven discusses a subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects at ASCO GI 2016 Â Â Â Â clinical trial, received tas-102, tas-102
ASH 2025 MDS/ALL Highlights: Verona Trial Lessons & CLEVER Pathway | Dr. Jeyakumar Acute Lymphoblastic Leukemia 5 Mins Read
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read